Conversion to combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy for renal dysfunction in liver transplant patients: Never too late?

Digestive Diseases and Sciences

Volumn 56, Issue 1, 2011, Pages 4-6

  Beckebaum, Susanne ^a   Cicinnati, Vito R ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; ENDOTHELIN; EVEROLIMUS; INTERSTITIAL COLLAGENASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; THROMBOXANE;

ANEMIA; B LYMPHOCYTE; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENZYME INHIBITION; GLOMERULOSCLEROSIS; GRAFT SURVIVAL; HUMAN; HYALINE DEGENERATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY TUBULE ATROPHY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; T LYMPHOCYTE;

CALCINEURIN; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; LIVER TRANSPLANTATION; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; TACROLIMUS;

EID: 79151472845     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-010-1449-1     Document Type: Review

References (24)

1. A Sethi RT Stravitz 2007 Review article: Medical management of the liver transplant recipient-A primer for non-transplant doctors Aliment Pharmacol Ther 25 229 245 1:CAS:528:DC%2BD2sXjtlelsbg%3D 10.1111/j.1365-2036.2006.03166.x 17217455
2. R Bahirwani KR Reddy 2009 Outcomes after liver transplantation: chronic kidney disease Liver Transpl 15 Suppl 2 S70 S74 10.1002/lt.21900 19876956
3. M Naesens DR Kuypers M Sarwal 2009 Calcineurin inhibitor nephrotoxicity Clin J Am Soc Nephrol 4 481 508 1:CAS:528:DC%2BD1MXjslagurc%3D 19218475
4. SA Farkas AA Schnitzbauer G Kirchner, et al. 2009 Calcineurin inhibitor minimization protocols in liver transplantation Transpl Int 22 49 60 10.1111/j.1432-2277.2008.00796.x 19121146
5. G Mells J Neuberger 2007 Reducing the risks of cardiovascular disease in liver allograft recipients Transplantation 83 1141 1150 10.1097/01.tp. 0000262706.28513.6a 17496526
6. M Shipkova VW Armstrong M Oellerich E Wieland 2005 Mycophenolate mofetil in organ transplantation: Focus on metabolism, safety and tolerability Expert Opin Drug Metab Toxicol 1 505 526 1:CAS:528:DC%2BD2MXhtVGjsLvF 10.1517/17425255.1.3.505 16863458
7. GP Pageaux L Rostaing Y Calmus, et al. 2006 Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation Liver Transpl 12 1755 1760 10.1002/lt.20903 17133564
8. VR Cicinnati Z Yu CG Klein, et al. 2007 Clinical trial: Switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients-Assessment of renal and allograft function, cardiovascular risk factors and immune monitoring Aliment Pharmacol Ther 26 1195 1208 1:CAS:528:DC%2BD2sXhtlyrsbbE 10.1111/j.1365-2036.2007.03466.x 17944734
9. AC Allison EM Eugui 2005 Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection Transplantation 80 S181 S190 1:CAS:528:DC%2BD2MXhtFGhsL7M 10.1097/01.tp.0000186390.10150.66 16251851
10. M Bahra UI Neumann D Jacob, et al. 2005 MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: Impact on histological course Am J Transplant 5 406 411 1:CAS:528:DC%2BD2MXhs1artrw%3D 10.1111/j.1600-6143. 2004.00706.x 15644002
11. S Iacob VR Cicinnati P Hilgard, et al. 2007 Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: Model to predict HCV cirrhosis after liver transplantation Transplantation 84 56 63 10.1097/01.tp.0000267916.36343.ca 17627238
12. N Roos N Poulalhon D Farge, et al. 2007 In vitro evidence for a direct anti-fibrotic role of the immunosupressive drug mycophenolate mofetil J Pharmacol Exp Ther 321 583 589 1:CAS:528:DC%2BD2sXltFehtbg%3D 10.1124/jpet.106.117051 17272676
13. C Badid M Vincent B McGregor, et al. 2000 Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney Kidney Int 58 51 61 1:CAS:528:DC%2BD3cXltVyjt7o%3D 10.1046/j.1523-1755.2000. 00140.x 10886549
14. SI van Leuven JJ Kastelein AC Allison MR Hayden ES Stroes 2006 Mycophenolate mofetil (MMF): Firing at the atherosclerotic plaque from different angles? Cardiovasc Res 69 341 347 10.1016/j.cardiores.2005.09.018 16289002
15. BJ Nankivell MD Wavamunno RJ Borrows, et al. 2007 Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology Am J Transplant 7 366 376 1:CAS:528:DC%2BD2sXhvFClsbY%3D 10.1111/j.1600-6143.2006. 01633.x 17283486
16. S Karie-Guigues N Janus F Saliba, et al. 2009 Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): The TRY study Liver Transpl 15 1083 1091 10.1002/lt.21803 19718632
17. A Jain R Vekatramanan B Eghtesad, et al. 2005 Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation Transplantation 80 859 864 1:CAS:528:DC%2BD2MXhtVynsbjI 10.1097/01.TP.0000173994.63299.63 16210976
18. M Biselli G Vitale A Gramenzi, et al. 2009 Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant Clin Transplant 23 191 198 10.1111/j.1399-0012.2009.00965.x 19210525
19. Kornberg A, Küpper B, Thrum K, et al. Sustained renal response to mycophenolate mofetil and CNI taper promotes survival in liver transplant patients with CNI-related renal dysfunction. Dig Dis Sci. 2010. doi: 10.1007/s10620-010-1386-z.
20. KJ Wood S Sakaguchi 2003 Regulatory T cells in transplantation tolerance Nat Rev Immunol 3 199 210 1:CAS:528:DC%2BD3sXitleqtL8%3D 10.1038/nri1027 12658268
21. R Zeiser VH Nguyen A Beilhack, et al. 2006 Inhibition of CD4 + CD25 + regulatory T-cell function by calcineurin-dependent interleukin-2 production Blood 108 390 399 1:CAS:528:DC%2BD28XmsVOlsrs%3D 10.1182/blood-2006-01-0329 16522809
22. A Demirkiran VD Sewgobind J van der Weijde, et al. 2009 Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4 + FOXP3 + regulatory T cells Transplantation 87 1062 1068 1:CAS:528:DC%2BD1MXktFCmu70%3D 10.1097/TP.0b013e31819d2032 19352129
23. A Kornberg B Kupper M Hommann J Scheele 2005 Introduction of MMF in conjunction with stepwise reduction of calcineurin inhibitor in stable liver transplant patients with renal dysfunction Int Immunopharmacol 5 141 146 1:CAS:528:DC%2BD2cXhtVKls73I 10.1016/j.intimp.2004.09.018 15589474
24. T Gerhardt B Terjung P Knipper, et al. 2009 Renal impairment after liver transplantation-A pilot trial of calcineurin inhibitor-free vs. calcineurin inhibitor sparing immunosuppression in patients with mildly impaired renal function after liver transplantation Eur J Med Res 14 210 215 1:CAS:528:DC%2BD1MXptVeisbc%3D 19541578